IMUX Q4 2023 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$135M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$23,000

Operating Income

-$23M

Net Income

-$22M

EPS (Diluted)

$-0.48

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$54M

Total Liabilities

$25M

Stockholders' Equity

$29M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$23,000	$0	—
Operating Income	-$23M	-$57M	+59.2%
Net Income	-$22M	-$56M	+61.8%